PTC Therapeutics Inc. announced on Friday it has named Matthew Klein to chief development officer and Eric Pauwels to chief business officer.
The South Plainfield-based biopharmaceutical firm said Klein will be tasked with developing clinical stage programs for the company. Pauwels will be responsible for customer-facing activities to ensure company therapies are available and accessible to rare disease patients worldwide.
“I am very pleased to announce these well-deserved appointments to PTC’s Executive Committee,” Stuart Peltz, CEO of PTC Therapeutics, said. “Matt and Eric are both recognized industry leaders with demonstrated track records of success. In their new roles, they will continue to advance our development pipeline, fuel our company’s growth and deliver on our mission to develop and provide transformative therapies for patients living with rare disorders.”
Klein, who’s been with PTC since last year and previously served as the global head of gene and mitochondrial therapies, previously served as the CEO and chief medical officer of BioElectron Technology Corp. Before that, he was the research chair of restorative burn surgery at the University of Washington.
Pauwels joined PTC in 2015 as senior vice president and general manager of the Americas. Before that, he was the chief commercial officer at NPS Pharmaceuticals and president of NPS Pharma International. PReviously, he served as senior vice president of global commercial operations at Shire Human Genetic Therapies.
